# Perrigo Company plc
Perrigo manufactures and distributes over-the-counter health and wellness products across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic categories, including upper respiratory treatments, pain relievers, digestive health remedies, oral care products, vitamins and supplements, women's health products, and skin care solutions. It operates under established consumer brands including Nasonex, Prevacid24HR, Mederma, Compeed, Dr. Fresh, and NiQuitin, among others. The company also provides contract manufacturing services for third parties.
Perrigo's operations are organized into two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. The company distributes its products through retail pharmacy chains, supermarkets, mass merchandise retailers, e-commerce platforms, wholesalers, and para-pharmacies. This multi-channel approach provides access to both traditional brick-and-mortar and digital sales channels.
The company employs approximately 8,100 full-time staff and operates as an Irish-incorporated entity headquartered in Dublin. Founded in 1887, Perrigo shifted to its current corporate domicile in 2013.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-10.29 | $-10.29 | -723.2% | |
| 2024 | $-1.25 | $-1.25 | -1288.9% | |
| 2023 | $-0.09 | $-0.09 | +91.3% | |
| 2022 | $-1.04 | $-1.04 | -100.0% | |
| 2021 | $-0.52 | $-0.52 | +59.7% | |
| 2020 | $-1.29 | $-1.29 | -821.4% | |
| 2019 | $-0.14 | $-0.14 | -123.3% | |
| 2018 | $0.60 | $0.60 | +106.3% | |
| 2016 | $-9.48 | $-9.48 | -2594.7% | |
| 2015 | $0.38 | $0.39 | -61.2% | |
| 2014 | $0.98 | $0.98 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001585364-26-000009 | SEC ↗ |
| 2024-12-31 | 2025-02-28 | 0001585364-25-000014 | SEC ↗ |
| 2023-12-31 | 2024-02-27 | 0001585364-24-000009 | SEC ↗ |
| 2022-12-31 | 2023-02-28 | 0001585364-23-000006 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001585364-22-000011 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001585364-21-000012 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001585364-20-000013 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001585364-19-000016 | SEC ↗ |
| 2017-12-31 | 2018-03-01 | 0001585364-18-000015 | SEC ↗ |
| 2016-12-31 | 2017-05-22 | 0001585364-17-000071 | SEC ↗ |